Get started
Author

Jason E. Hill

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
2006 · Wenle Xia, Sarah Bacus, et al. · Proceedings of the National Academy of Sciences · 373
ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
2010 · Neru Munshi, Sébastien Jeay, et al. · Molecular Cancer Therapeutics · 326
Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κB-dependent mechanism of p53 suppression in tumors
2005 · Katerina V. Gurova, Jason E. Hill, et al. · Proceedings of the National Academy of Sciences · 265
PCR-based subtractive hybridization and differences in gene content among strains of Helicobacter pylori
1998 · Natalia S. Akopyants, Arkady Fradkov, et al. · Proceedings of the National Academy of Sciences · 235
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3
2024 · Mark J. Levis, Mehdi Hamadani, et al. · Journal of Clinical Oncology · 225
A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations
2018 · Mark J. Levis, Alexander E. Perl, et al. · Blood Advances · 152
PDF
Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53
1998 · Elena A Komarova, Luda Diatchenko, et al. · Oncogene · 140
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy
2022 · Eunice S. Wang, Pau Montesinos, et al. · Blood · 139
PDF
Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells
2007 · Neil L. Spector, Yosef Yarden, et al. · Proceedings of the National Academy of Sciences · 117
Discovery and Optimization of a Series of 3-(3-Phenyl-3 H -imidazo[4,5- b ]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors
2012 · Mark A. Ashwell, Jean-Marc Lapierre, et al. · Journal of Medicinal Chemistry · 111
p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism
2004 · Katerina V. Gurova, Jason E. Hill, et al. · Cancer Research · 108
Molecular profile of FLT3 -mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
2022 · Catherine C. Smith, Mark J. Levis, et al. · Blood Advances · 96
PDF
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
2020 · Theodore C. Tarver, Jason E. Hill, et al. · Blood Advances · 80
PDF
A Large Set of Finnish Affected Sibling Pair Families With Type 2 Diabetes Suggests Susceptibility Loci on Chromosomes 6, 11, and 14
2004 · Kaisa Silander, Laura J. Scott, et al. · Diabetes · 77
PDF
Structure and Regulation of the Mouse ing1 Gene
1999 · Marija Zeremski, Jason E. Hill, et al. · Journal of Biological Chemistry · 63
PDF
Down-Regulation of p53 by Double-Stranded RNA Modulates the Antiviral Response
2005 · Joao T. Marques, Dominique Rebouillat, et al. · Journal of Virology · 59
Inhibition of p53 Response in Tumor Stroma Improves Efficacy of Anticancer Treatment by Increasing Antiangiogenic Effects of Chemotherapy and Radiotherapy in Mice
2006 · Lyudmila G. Burdelya, Elena A. Komarova, et al. · Cancer Research · 55
PDF
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML
2025 · Mark J. Levis, Mehdi Hamadani, et al. · Blood · 53
PDF
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML
2023 · Keith W. Pratz, Mohamad Cherry, et al. · Journal of Clinical Oncology · 51
PDF
A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2019 · Mari C. Vázquez-Borrego, Vandana Gupta, et al. · Clinical Cancer Research · 50
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
2009 · Susan A J Vaziri, Dale R Grabowski, et al. · PubMed · 32
Sensitization of DNA damage–induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3σ and survivin
2005 · Susan A.J. Vaziri, Jason Hill, et al. · Molecular Cancer Therapeutics · 32
Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy
2010 · Christina M. Coughlin, Daniel S. Johnston, et al. · Breast Cancer Research and Treatment · 31
Downregulation of topoisomerase IIβ in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest
2006 · K Chikamori, J E Hill, et al. · Leukemia · 31
A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results
2020 · Keith W. Pratz, Mohamad Cherry, et al. · Blood · 30
Works count: 65
Citation count: 3,131
H-index: 25
I10-index: 34
Year
Topic
Type